Literature DB >> 23295949

Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice.

Sofia Benkhelifa-Ziyyat1, Aurore Besse, Marianne Roda, Sandra Duque, Stéphanie Astord, Romain Carcenac, Thibaut Marais, Martine Barkats.   

Abstract

We have recently demonstrated the remarkable efficiency of self-complementary (sc) AAV9 vectors for central nervous system (CNS) gene transfer following intravenous delivery in mice and larger animals. Here, we investigated whether gene delivery to motor neurons (MNs) could also be achieved via intramuscular (i.m.) scAAV9 injection and subsequent retrograde transport along the MNs axons. Unexpectedly, we found that a single injection of scAAV9 into the adult mouse gastrocnemius (GA) mediated widespread MN transduction along the whole spinal cord, without limitation to the MNs connected to the injected muscle. Spinal cord astrocytes and peripheral organs were also transduced, indicating vector spread from the injected muscle to both the CNS and the periphery through release into the blood circulation. Moreover, we showed that i.m. injection of scAAV9 vectors expressing "survival of motor neuron" (Smn) in spinal muscular atrophy (SMA) mice mediated high survival motor neuron (SMN) expression levels at both the CNS and the periphery, and increased the median lifespan from 12 days to 163 days. These findings represent to date the longest extent in survival obtained in SMA mice following i.m. viral vector gene delivery, and might generate a renewed interest in the use of i.m. adeno-associated viruses (AAV) delivery for the development of gene therapy strategies for MN diseases.

Entities:  

Mesh:

Year:  2013        PMID: 23295949      PMCID: PMC3594018          DOI: 10.1038/mt.2012.261

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  46 in total

1.  Targeting functional subtypes of spinal motoneurons and skeletal muscle fibers in vivo by intramuscular injection of adenoviral and adeno-associated viral vectors.

Authors:  Vladimir N Martinov; Iren Sefland; S Ivar Walaas; Terje Lømo; Arild Njå; Frank Hoover
Journal:  Anat Embryol (Berl)       Date:  2002-04-27

2.  Specific and efficient gene transfer strategy offers new potentialities for the treatment of motor neurone diseases.

Authors:  F Finiels; M Gimenez y Ribotta; M Barkats; M L Samolyk; J J Robert; A Privat; F Revah; J Mallet
Journal:  Neuroreport       Date:  1995-12-29       Impact factor: 1.837

3.  A mouse model for spinal muscular atrophy.

Authors:  H M Hsieh-Li; J G Chang; Y J Jong; M H Wu; N M Wang; C H Tsai; H Li
Journal:  Nat Genet       Date:  2000-01       Impact factor: 38.330

4.  Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery.

Authors:  N D Mazarakis; M Azzouz; J B Rohll; F M Ellard; F J Wilkes; A L Olsen; E E Carter; R D Barber; D F Baban; S M Kingsman; A J Kingsman; K O'Malley; K A Mitrophanous
Journal:  Hum Mol Genet       Date:  2001-09-15       Impact factor: 6.150

5.  Prevention of motoneuron death by adenovirus-mediated neurotrophic factors.

Authors:  M Giménez y Ribotta; F Revah; L Pradier; I Loquet; J Mallet; A Privat
Journal:  J Neurosci Res       Date:  1997-05-01       Impact factor: 4.164

6.  Transfer of contaminants in adeno-associated virus vector stocks can mimic transduction and lead to artifactual results.

Authors:  I E Alexander; D W Russell; A D Miller
Journal:  Hum Gene Ther       Date:  1997-11-01       Impact factor: 5.695

7.  Identification and characterization of a spinal muscular atrophy-determining gene.

Authors:  S Lefebvre; L Bürglen; S Reboullet; O Clermont; P Burlet; L Viollet; B Benichou; C Cruaud; P Millasseau; M Zeviani
Journal:  Cell       Date:  1995-01-13       Impact factor: 41.582

8.  Intramuscular injection of AAV-GDNF results in sustained expression of transgenic GDNF, and its delivery to spinal motoneurons by retrograde transport.

Authors:  Yan-Yan Lu; Li-Jun Wang; Shin-ichi Muramatsu; Kunihiko Ikeguchi; Ken-ichi Fujimoto; Takashi Okada; Hiroaki Mizukami; Takashi Matsushita; Yutaka Hanazono; Akihiro Kume; Toshiharu Nagatsu; Keiya Ozawa; Imaharu Nakano
Journal:  Neurosci Res       Date:  2003-01       Impact factor: 3.304

9.  Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model.

Authors:  Brian K Kaspar; Jerònia Lladó; Nushin Sherkat; Jeffrey D Rothstein; Fred H Gage
Journal:  Science       Date:  2003-08-08       Impact factor: 47.728

10.  VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model.

Authors:  Mimoun Azzouz; G Scott Ralph; Erik Storkebaum; Lucy E Walmsley; Kyriacos A Mitrophanous; Susan M Kingsman; Peter Carmeliet; Nicholas D Mazarakis
Journal:  Nature       Date:  2004-05-27       Impact factor: 49.962

View more
  55 in total

1.  Intramuscular Injections Along the Motor End Plates: A Minimally Invasive Approach to Shuttle Tracers Directly into Motor Neurons.

Authors:  Rahul Mohan; Andrew P Tosolini; Renée Morris
Journal:  J Vis Exp       Date:  2015-07-13       Impact factor: 1.355

Review 2.  Spinal muscular atrophy: an update on therapeutic progress.

Authors:  Joonbae Seo; Matthew D Howell; Natalia N Singh; Ravindra N Singh
Journal:  Biochim Biophys Acta       Date:  2013-08-27

3.  Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice.

Authors:  Brett D Dufour; Catherine A Smith; Randall L Clark; Timothy R Walker; Jodi L McBride
Journal:  Mol Ther       Date:  2014-01-06       Impact factor: 11.454

4.  AAV-PHP.B Administration Results in a Differential Pattern of CNS Biodistribution in Non-human Primates Compared with Mice.

Authors:  William A Liguore; Jacqueline S Domire; Dana Button; Yun Wang; Brett D Dufour; Sathya Srinivasan; Jodi L McBride
Journal:  Mol Ther       Date:  2019-08-05       Impact factor: 11.454

Review 5.  Challenges of gene delivery to the central nervous system and the growing use of biomaterial vectors.

Authors:  Devan L Puhl; Anthony R D'Amato; Ryan J Gilbert
Journal:  Brain Res Bull       Date:  2019-06-05       Impact factor: 4.077

Review 6.  Advances in therapeutic development for spinal muscular atrophy.

Authors:  Matthew D Howell; Natalia N Singh; Ravindra N Singh
Journal:  Future Med Chem       Date:  2014-06       Impact factor: 3.808

7.  Specific retrograde transduction of spinal motor neurons using lentiviral vectors targeted to presynaptic NMJ receptors.

Authors:  I Eleftheriadou; A Trabalza; S M Ellison; K Gharun; N D Mazarakis
Journal:  Mol Ther       Date:  2014-03-26       Impact factor: 11.454

8.  Drug treatment for spinal muscular atrophy types II and III.

Authors:  Renske I Wadman; W Ludo van der Pol; Wendy Mj Bosboom; Fay-Lynn Asselman; Leonard H van den Berg; Susan T Iannaccone; Alexander Fje Vrancken
Journal:  Cochrane Database Syst Rev       Date:  2020-01-06

9.  Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice.

Authors:  Mai K Elmallah; Darin J Falk; Sushrusha Nayak; Roland A Federico; Milapjit S Sandhu; Amy Poirier; Barry J Byrne; David D Fuller
Journal:  Mol Ther       Date:  2013-12-12       Impact factor: 11.454

Review 10.  Gene Therapy Strategies to Restore ER Proteostasis in Disease.

Authors:  Vicente Valenzuela; Kasey L Jackson; Sergio P Sardi; Claudio Hetz
Journal:  Mol Ther       Date:  2018-04-07       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.